heparin

(redirected from Low molecular weight heparin)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.
Related to Low molecular weight heparin: Enoxaparin

heparin

(hĕp`ərĭn), anticoagulantanticoagulant
, any of several substances that inhibit blood clot formation (see blood clotting). Some anticoagulants, such as the coumarin derivatives bishydroxycoumarin (Dicumarol) and warfarin (Coumadin) inhibit synthesis of prothrombin, a clot-forming substance, and other
..... Click the link for more information.
 produced by cells in many animals. A polysaccharide, heparin is found in the human body and occurs in greatest concentration in the tissues surrounding the capillaries of the lungs and the liver. The substance, extracted from animal tissues, is used clinically to delay blood clottingblood clotting,
process by which the blood coagulates to form solid masses, or clots. In minor injuries, small oval bodies called platelets, or thrombocytes, tend to collect and form plugs in blood vessel openings.
..... Click the link for more information.
.
The Columbia Electronic Encyclopedia™ Copyright © 2013, Columbia University Press. Licensed from Columbia University Press. All rights reserved. www.cc.columbia.edu/cu/cup/

heparin

[′hep·ə·rən]
(biochemistry)
An acid mucopolysaccharide acting as an antithrombin, antithromboplastin, and antiplatelet factor to prolong the clotting time of whole blood; occurs in a variety of tissues, most abundantly in liver.
McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
Browse 44 Market Data Tables and 39 Figures spread through 218 Pages and in-depth TOC on "Low Molecular Weight Heparin Market, by Drug (Enoxaparin, Dalteparin, Nadroparin, Bemiparin, Tinzaparin, and Others), by Packaging (Multi-vials and Prefilled Syringes), by Application (Deep Vein Thrombosis, Acute Coronary Syndrome (ACS), Pulmonary Embolism, and Atrial Fibrillation), by End Use (Hospitals (Private and Public), Clinics, and Home), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026"
Low molecular weight heparin treatment of acute moderate and severe pancreatitis: A randomized, controlled, open-label study.
Yin, "Gambogic acid grafted low molecular weight heparin micelles for targeted treatment in a hepatocellular carcinoma model with an enhanced anti-angiogenesis effect," International Journal of Pharmaceutics, vol.
Caption: Figure 3: Effects of low molecular weight heparin nebulization on ratio of lung wet/dry weight.
Low molecular weight heparins; differences and similarities in approved preparations in the United States.
Leyvraz PF, Bachmann F, Hoek J et al 1991 Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin British Medical Journal 303 (6802) 543-548
Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy: a case series.
If continued anticoagulation is required, alternative therapies are available such as low molecular weight heparin (LMWH), enoxaparin sodium/Lovenox[R], or the heparinoid, danaparoid sodium/Orgaran[R].
The global heparin anticoagulant market segmentation is based on products (unfractionated heparin, low molecular weight heparin, ultra-low molecular weight heparin).
If warfarin is not tolerated or there is a contraindication to its use, low molecular weight heparin (LMWH) serves as an alternative option (Hughes, Szeki, Nash, & Thachil, 2014).
27 September 2011 - US biotechnology company PolyMedix Inc (OTCBB:PYMX) said today that it had begun a Phase Ib/II trial to assess the safety and efficacy of PMX-60056 in reversing the anticoagulant activity of enoxaparin (Lovenox), a low molecular weight heparin (LMWH).

Full browser ?